SGLT-2抑制剂和GLP-1受体激动剂的联合使用_替代终点和硬终点的潜在好处.pdf,1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agoni
持续葡萄糖监测(CGM)能提供连续、全面、可靠的血糖情况,发现不易被传统监测方法所探测到的隐匿性高血糖和低血糖,同时提供 TIR 等信息,过去常用于胰岛素治疗的 1 型或 2 型糖尿病(T1DM/T2DM)患者的血糖监测[4]。而胰高糖素样肽-1...
the cellular mechanisms associated with CV protection afforded by these agents, investigating a pleiotropic range of potential effects to improve bone marrow (BM), kidney, heart, and vascular health. Additionally, there is gr...
持续葡萄糖监测(CGM)能提供连续、全面、可靠的血糖情况,发现不易被传统监测方法所探测到的隐匿性高血糖和低血糖,同时提供 TIR 等信息,过去常用于胰岛素治疗的 1 型或 2 型糖尿病(T1DM/T2DM)患者的血糖监测[4]。而胰高糖素样肽-1 受体激动剂(GLP-1RA)和钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)等控糖新药,...
Of the currently available glucose-lowering therapies, sodium鈥揼lucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) both provide effective glycemic control and have been shown to reduce cardiovascular (CV) events in patients with T2D and a high ...
Since sodium/glucose cotransporter-2 (SGLT-2) inhibitor treatment reduces CV events as well (with the effect mainly driven by a reduction in heart failure complications), the individual risk of ischemic or heart failure complications should guide the choice of treatment. GLP-1 RAs may also help...
In contrast, the effects of glucose on GLP-1 secretion, depending on co-transport with Na+ via sodium-glucose transporter 1 (SGLT1), is strongly inhibited by this maneuver [20]. However, other possible uptake mechanisms, such as l-valine coupled to H+, deserve further investigation. Though...
control have been explored. GLP-1R agonist and sodium-glucose cotransporter-2 inhibitor (SGLT2) inhibitors approved for diabetes also show early efficacy in NASH [36,37]. For example, while cotadutide (a dual agonist at GLP-1R and glucagon receptor, GCGR) reduces body weight, inhibits food ...
Inflammation is a well-known cardiovascular risk factor acting as a facilitator for atherosclerosis and atherosclerotic plaque rupture. Cardiovascular (CV) events are strongly related to interleukin-6 (IL-6) and C-reactive protein (CRP), independently from the classical CV risk factors [1,2,3,4]...
Here, we summarise clinical inertia as a key barrier to increased use of SGLT2i and GLP-1 RA in eligible, at-risk patients in post-CVOT diabetes care. By doing so, we hope to alert the community to the urgency of the cardiorenal crisis, and the need to do more to mitigate risk in...